Blood-Brain Barrier Market By Disease Type (Alzheimer’s Disease, Epilepsy, Parkinson’s Disease, Multiple Sclerosis, Hunter’s Syndrome, Brain Cancer), By Technology (Bispecific Antibody RMT Approach, Trojan Horse Approach, Increasing The Permeability Of BBB, Passive Diffusion, Other) - Growth, Share, Opportunities & Competitive Analysis, 2018 – 2026
Industry Outlook
The global blood-brain barrier market projected to reach US$ 5,704.2 Mn by 2026 from US$ 696.4 Mn in 2017, growing at a CAGR of 25.0% during the forecast period from 2018 to 2026. The blood-brain barrier (BBB) prevents free flow of elements from circulatory system to the cerebrospinal fluid (CSF) or brain with specific exchange of elements regulated by blood-brain barrier and blood-CSF barrier. They key components of BBB are endothelial cells, capillary basement membrane, astrocytes, and pericytes. Physiologically water, CO2, oxygen and lipid soluble molecules are capable of travelling across the blood-brain barrier; adenosine triphosphate (ATP) produced by mitochondria carries out the active transport.
Alzheimer’s & Parkinson Diseases are the most prevalent diseases assisting the growth of blood-brain barrier market
In year 2016, epilepsy, Alzheimer’s and Parkinson’s disease dominated the market with more than 50% of the market share collectively owing to increasing prevalence of these diseases, introduction of novel diagnostic technology for these diseases, and rising awareness programs organized by governmental and non-governmental organizations is assisting the growth of diagnostic market of these diseases. In addition, increasing geriatric population and rising prevalence of lifestyle-specific CNS disorders are assisting the growth of global demand for blood-brain barrier technologies. According to Sanofi S.A., Epilepsy is the most common neurological disorder affecting about 20-50 million people worldwide. The disease is more frequent in children than in adults, the highest incidence being in the neonatal period of life, and then declining markedly before rising in the old age. During the forecast period 2018 to 2026, Asia Pacific identified as the fastest growing blood-brain barrier market due to major driving factors such as mounting prevalence and incidence of diseases affecting central nervous system in geriatric population.
Technological advancements and rising accessibility to modern technology in developing countries of Asia Pacific is driving the market growth
In base year 2016, North America accounted for the largest share in global blood-brain barrier market due to key driving factors such as rising prevalence of neurological diseases, supportive reimbursement policies, high awareness related to early neurological disease diagnosis and treatment, and incessant developments in the field of blood-brain barrier technologies research and development. According to a research report, an estimated 5.4 million Americans have Alzheimer’s disease and today someone in America develops Alzheimer’s disease every 68 seconds. By 2050, it is expected that one new case of Alzheimer’s disease will be diagnosed for every 33 seconds, or nearly a million new cases per year, and Alzheimer’s disease global prevalence is projected to reach 16 million. During the forecast period 2018 to 2026, Asia Pacific was identified as the fastest growing BBB market due to key driving factors such as increasing prevalence of CNS disorders, rapidly evolving healthcare infrastructure, and rising awareness associated with neurological diseases. Thus, increasing awareness is fueling the rate of diagnosis, and mounting accessibility of patients to modern treatment solutions especially observed in developing countries of this region.
Blood-brain barrier technologies are developing rapidly and its pipeline is very strong
The blood-brain barrier comprises technologies as follows:
- SonoCloud – (Phase I/IIa)
- MRI-guided laser ablation + Doxorubicin + Etoposide + Dynamic contrast-enhanced (DCE) MRI – (Phase I)
- P03277 + Gadobenate dimeglumine + MRI – (Phase II Completed)
- Carboplatin + Mannitol + Melphalan + Sodium Thiosulfate – (Phase I/II)
- Intra-arterial Cerebral Infusion of Trastuzumab (Phase I)
- 25% Mannitol + Low-dose Intra-arterial Bevacizumab – (Phase II)
The most promising products in this list are SonoCloud, and P03277 + Gadobenate dimeglumine, SonoCloud is owned by CARTHERA, and Guerbet owns P03277 + Gadobenate dimeglumine.
This report further describes the major qualitative assessment factors including key market trends, market drivers & restraints, to assist in better understanding of global blood-brain barrier market. Furthermore, the key players analyzed graphically based on their product offering, market strategies and business strength. The report also provides attractive investment proposition based on the extensive geographical research carried out based on PESTEL analysis. Key players profiled in the report include Allon Therapeutics, Inc., Angiochem Inc., Armagen Technologies, Inc., BrainsGate, Bristol-Myers Squibb, BiOasis Technologies, Inc., Sanofi Genzyme, CarThera, Cephalon Inc., F. Hoffman La-Roche, Janssen Pharmaceutica NV, and others.
Key questions answered in this report
- Which are the key blood-brain barrier technologies?
- Which pipeline products are most promising in the near future and expected to be launch by 2026?
- What are the current market trends in the blood-brain barrier industry and evolving growth opportunities for the companies operating in this market?
- Which are the most attractive countries in Asia Pacific and other developing regions?
- North America blood-brain barrier market size and effect of latest technologies and upcoming technologies in this market?
Chapter 1. Preface
1.1. Report Scope and Description
1.2. Research Methodology
1.2.1. Phase I-Secondary Research
1.2.2. Phase II-Primary Research
1.2.3. Phase III-Expert Panel Review
1.2.4. Assumptions
1.2.5. Approach Adopted
Chapter 2. Executive Summary
2.1. Global Blood-Brain Barrier Market Portraiture
2.2. Global Blood-Brain Barrier Market, By Disease Type, 2017 (US$ Mn)
2.3. Global Blood-Brain Barrier Market, By Technology Type, 2017 (US$ Mn)
2.4. Global Blood-Brain Barrier Market, by Geography, 2017 Vs 2026 (Value %)
Chapter 3. Global Blood-Brain Barrier Market: Market Dynamics and Future Outlook
3.1. Market Overview
3.2. Blood-Brain Barrier Technologies: Future Trends
3.3. Current Scenario: Strategies Used for Drug Delivery Across BBB Drivers
3.4. Challenges
3.5. Opportunities
3.6. Attractive Investment Proposition, by Geography, 2017
3.7. Major Agreements, Partnerships and Collaborations
3.8. Competitive Landscape
3.8.1. Competitive Landscape, by Key Players, 2017
Chapter 4. Global Blood-Brain Barrier Market, by Disease Type, 2016 – 2026 (US$ Mn)
4.1. Overview
4.2. Alzheimer’s Disease
4.3. Epilepsy
4.4. Parkinson’s Disease
4.5. Multiple Sclerosis
4.6. Hunter’s Syndrome
4.7. Brain Cancer
Chapter 5. Global Blood-Brain Barrier Market, By Technology, 2016 – 2026 (US$)
5.1. Overview
5.2. Bispecific Antibody RMT Approach
5.2.1. Ossianix Blood-Brain Barrier Technology (Ossianix)
5.2.2. Brain Shuttle Technology (Roche)
5.2.3. Other Bispecific Antibodies Based Technologies
5.3. Trojan Horse Approach
5.3.1. Transcend Technology (biOasis)
5.3.2. LRP Technology (Angiochem)
5.3.3. IPRO Technology (Iproteos)
5.3.4. ArmaGen Technology Platform (ArmaGen)
5.3.5. Vect-Horus Technology Platform (Vect-Horus)
5.3.6. G-Technology (BBB Therapeutics)
5.3.7. Nano BBB Technology Platform (Sagetis Biotech)
5.3.8. Other Technologies Based on Trojan Horse Approach
5.4. Increasing the Permeability of BBB
5.4.1. SonoCloud Technology (CarThera)
5.4.2. SPG Technology (BrainsGate)
5.4.3. Other Technologies Based on Increasing Permeability of BBB
5.5. Passive Diffusion
5.5.1. SciFluor Life Sciences
5.6. Other Non-Invasive BBB Technologies
5.6.1. SMART Molecule Technology (ICBI)
5.6.2. Molecular Envelope Technology (Nanomerics)
5.6.3. Other Approaches (JCR Pharma, Cyclenium, Cerecor, Lauren Sciences, Protheragen)
Chapter 6. Global Blood-Brain Barrier Market: Pipeline Analysis
6.1. Overview
6.2. SonoCloud
6.3. MRI-guided laser ablation + Doxorubicin + Etoposide + Dynamic contrast-enhanced (DCE) MRI
6.4. P03277 + Gadobenate dimeglumine + MRI
6.5. Carboplatin + Mannitol + Melphalan + Sodium Thiosulfate
6.6. Intra-arterial Cerebral Infusion of Trastuzumab
6.7. 25% Mannitol + Low-dose Intra-arterial Bevacizumab
Chapter 7. Global Blood-Brain Barrier Market, by Geography, 2016 – 2026 (US$ Mn)
7.1. Overview
7.2. North America Blood-Brain Barrier Market Analysis, 2016 – 2026
7.2.1. North America Blood-Brain Barrier Market, By Disease Type, 2016 – 2026 (US$ Mn)
7.2.2. North America Blood-Brain Barrier Market, By Technology Type, 2016 – 2026 (US$ Mn)
7.2.3. North America Blood-Brain Barrier Market, by Country, 2016 – 2026 (US$ Mn)
7.2.3.1. U.S.
7.2.3.2. Canada
7.3. Europe Blood-Brain Barrier Market Analysis, 2016 – 2026
7.3.1. Europe Blood-Brain Barrier Market, By Disease Type, 2016 – 2026 (US$ Mn)
7.3.2. Europe Blood-Brain Barrier Market, By Technology Type, 2016 – 2026 (US$ Mn)
7.3.3. Europe Blood-Brain Barrier Market, by Country, 2016 – 2026 (US$ Mn)
7.3.3.1. U.K.
7.3.3.2. Germany
7.3.3.3. Rest of Europe
7.4. Asia Pacific Blood-Brain Barrier Market Analysis, 2016 – 2026
7.4.1. Asia Pacific Blood-Brain Barrier Market, By Disease Type, 2016 – 2026 (US$ Mn)
7.4.2. Asia Pacific Blood-Brain Barrier Market, By Technology Type, 2016 – 2026 (US$ Mn)
7.4.3. Asia Pacific Blood-Brain Barrier Market, by Country, 2016 – 2026 (US$ Mn)
7.4.3.1. Japan
7.4.3.2. China
7.4.3.3. Rest of APAC
7.5. Latin America Blood-Brain Barrier Market Analysis, 2016 – 2026
7.5.1. Latin America Blood-Brain Barrier Market, By Disease Type, 2016 – 2026 (US$ Mn)
7.5.2. Latin America Blood-Brain Barrier Market, By Technology Type, 2016 – 2026 (US$ Mn)
7.5.3. Latin America Blood-Brain Barrier Market, by Country, 2016 – 2026 (US$ Mn)
7.5.3.1. Brazil
7.5.3.2. Mexico
7.5.3.3. Rest of Latin America
7.6. Middle East & Africa (MEA) Blood-Brain Barrier Market Analysis, 2016 – 2026
7.6.1. MEA Blood-Brain Barrier Market, by Disease Type, 2016 – 2026 (US$ Mn)
7.6.2. MEA Blood-Brain Barrier Market, By Technology Type, 2016 – 2026 (US$ Mn)
7.6.3. MEA Blood-Brain Barrier Market, by Region, 2016 – 2026 (US$ Mn)
7.6.3.1. GCC
7.6.3.2. Rest of MEA
Chapter 8. Company Profiles
8.1. Allon Therapeutics, Inc.
8.1.1. Business Description
8.1.2. Financial Information (Subject to data availability)
8.1.3. Product Portfolio
8.1.4. Key Developments
8.2. Angiochem Inc.
8.3. Armagen Technologies, Inc.
8.4. BrainsGate
8.5. Bristol-Myers Squibb
8.6. BiOasis Technologies, Inc.
8.7. Cephalon Inc.
8.8. Cerecor
8.9. CarThera
8.10. Cytos Biotechnology AG
8.11. Envivo Pharmaceuticals, Inc.
8.12. Eli Lilly And Company
8.13. Sanofi Genzyme
8.14. Iproteos S.L.
8.15. Janssen Pharmaceutica NV
8.16. Nanomerics
8.17. Ossianix, Inc.
8.18. Protheragen, Inc.
8.19. F. Hoffman La-Roche
8.20. Shire plc
TABLE 1 Global Blood-Brain Barrier Market, By Disease Type, 2016 – 2026 (US$ Mn)
TABLE 2 Global Blood-Brain Barrier Market, By Technology Type, 2016 – 2026 (US$ Mn)
TABLE 3 Global Blood-Brain Barrier Market, By Geography, 2016 – 2026 (US$ Mn)
TABLE 4 North America Blood-Brain Barrier Market, By Disease Type, 2016 – 2026 (US$ Mn)
TABLE 5 North America Blood-Brain Barrier Market, By Technology Type, 2016 – 2026 (US$ Mn)
TABLE 6 North America Blood-Brain Barrier Market, By Country, 2016 – 2026 (US$ Mn)
TABLE 7 Europe Blood-Brain Barrier Market, By Disease Type, 2016 – 2026 (US$ Mn)
TABLE 8 Europe Blood-Brain Barrier Market, By Technology Type, 2016 – 2026 (US$ Mn)
TABLE 9 Europe Blood-Brain Barrier Market, By Country, 2016 – 2026 (US$ Mn)
TABLE 10 Asia Pacific Blood-Brain Barrier Market, By Disease Type, 2016 – 2026 (US$ Mn)
TABLE 11 Asia Pacific Blood-Brain Barrier Market, By Technology Type, 2016 – 2026 (US$ Mn)
TABLE 12 Asia Pacific Blood-Brain Barrier Market, By Country, 2016 – 2026 (US$ Mn)
TABLE 13 Latin America Blood-Brain Barrier Market, By Disease Type, 2016 – 2026 (US$ Mn)
TABLE 14 Latin America Blood-Brain Barrier Market, By Technology Type, 2016 – 2026 (US$ Mn)
TABLE 15 Latin America Blood-Brain Barrier Market, By Country, 2016 – 2026 (US$ Mn)
TABLE 16 Middle East And Africa Blood-Brain Barrier Market, By Disease Type, 2016 – 2026 (US$ Mn)
TABLE 17 Middle East And Africa Blood-Brain Barrier Market, By Technology Type, 2016 – 2026 (US$ Mn)
TABLE 18 Middle East And Africa Blood-Brain Barrier Market, by Region, 2016 – 2026 (US$ Mn)
TABLE 19 Allon Therapeutics, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 20 Angiochem Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 21 Armagen Technologies, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 22 BrainsGate: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 23 Bristol-Myers Squibb: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 24 BiOasis Technologies, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 25 Cephalon Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 26 Cerecor: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 27 CarThera: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 28 Cytos Biotechnology AG: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 29 Envivo Pharmaceuticals, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 30 Eli Lilly And Company: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 31 Sanofi Genzyme: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 32 Iproteos S.L.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 33 Janssen Pharmaceutica NV: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 34 Nanomerics: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 35 Ossianix, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 36 Protheragen, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 37 F. Hoffman La-Roche: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 38 Shire plc: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
FIG. 1 Blood-Brain Barrier: Market Segmentation
FIG. 2 Global Blood-Brain Barrier Market Share, By Disease Type, 2017 (US$ Mn)
FIG. 3 Global Blood-Brain Barrier Market Share, By Technology Type, 2017 (US$ Mn)
FIG. 4 Global Blood-Brain Barrier Market, by Geography, 2017 Vs 2026 (Value %)
FIG. 5 Attractive Investment Proposition, by Geography, 2017
FIG. 6 Market Competition Landscape, by Key Players, 2017
FIG. 7 Global Blood-Brain Barrier Market for Alzheimer’s Disease, 2016 – 2026 (US$ Mn)
FIG. 8 Global Blood-Brain Barrier Market for Epilepsy, 2016 – 2026 (US$ Mn)
FIG. 9 Global Blood-Brain Barrier Market for Parkinson’s Disease, 2016 – 2026 (US$ Mn)
FIG. 10 Global Blood-Brain Barrier Market for Multiple Sclerosis, 2016 – 2026 (US$ Mn)
FIG. 11 Global Blood-Brain Barrier Market for Hunter’s Syndrome, 2016 – 2026 (US$ Mn)
FIG. 12 Global Blood-Brain Barrier Market for Brain Cancer, 2016 – 2026 (US$ Mn)
FIG. 13 Global Ossianix Blood-Brain Barrier Technology Market, 2016 – 2026 (US$ Mn)
FIG. 14 Global Brain Shuttle Technology Market, 2016 – 2026 (US$ Mn)
FIG. 15 Global Other Bispecific Antibodies Based Technologies Market, 2016 – 2026 (US$ Mn)
FIG. 16 Global Transcend Technology Market, 2016 – 2026 (US$ Mn)
FIG. 17 Global LRP Technology Market, 2016 – 2026 (US$ Mn)
FIG. 18 Global IPRO Technology Market, 2016 – 2026 (US$ Mn)
FIG. 19 Global ArmaGen Technology Platform Market, 2016 – 2026 (US$ Mn)
FIG. 20 Global Vect-Horus Technology Platform Market, 2016 – 2026 (US$ Mn)
FIG. 21 Global G-Technology Market, 2016 – 2026 (US$ Mn)
FIG. 22 Global Nano BBB Technology Platform Market, 2016 – 2026 (US$ Mn)
FIG. 23 Global Other Technologies Based on Trojan Horse Approach Market, 2016 – 2026 (US$ Mn)
FIG. 24 Global SonoCloud Technology Market, 2016 – 2026 (US$ Mn)
FIG. 25 Global SPG Technology Market, 2016 – 2026 (US$ Mn)
FIG. 26 Global Other Technologies Based on Increasing Permeability of BBB Market, 2016 – 2026 (US$ Mn)
FIG. 27 Global SciFluor Life Sciences Market, 2016 – 2026 (US$ Mn)
FIG. 28 Global SMART Molecule Technology Market, 2016 – 2026 (US$ Mn)
FIG. 29 Global Molecular Envelope Technology Market, 2016 – 2026 (US$ Mn)
FIG. 30 Global Other Approaches Market, 2016 – 2026 (US$ Mn)
FIG. 31 U.S. Blood-Brain Barrier Market, 2016 – 2026 (US$ Mn)
FIG. 32 Canada Blood-Brain Barrier Market, 2016 – 2026 (US$ Mn)
FIG. 33 U.K. Blood-Brain Barrier Market, 2016 – 2026 (US$ Mn)
FIG. 34 Germany Blood-Brain Barrier Market, 2016 – 2026 (US$ Mn)
FIG. 35 Rest Of Europe Blood-Brain Barrier Market, 2016 – 2026 (US$ Mn)
FIG. 36 Japan Blood-Brain Barrier Market, 2016 – 2026 (US$ Mn)
FIG. 37 China Blood-Brain Barrier Market, 2016 – 2026 (US$ Mn)
FIG. 38 Rest Of Asia Pacific Blood-Brain Barrier Market, 2016 – 2026 (US$ Mn)
FIG. 39 Brazil Blood-Brain Barrier Market, 2016 – 2026 (US$ Mn)
FIG. 40 Mexico Blood-Brain Barrier Market, 2016 – 2026 (US$ Mn)
FIG. 41 Rest Of Latin America Blood-Brain Barrier Market, 2016 – 2026 (US$ Mn)
FIG. 42 GCC Blood-Brain Barrier Market, 2016 – 2026 (US$ Mn)
FIG. 43 Rest Of Middle East And Africa Blood-Brain Barrier Market, 2016 – 2026 (US$ Mn)
Choose License
Contact Information
: sales@briskinsights.com
: +448081890034 (UK)